• AAPL 181.71
  • TSLA 184.76
  • AMZN 188.7
  • MSFT 413.54
  • INTC 30.97
  • EURUSD 1.0772
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PA /
  3. ALQGC.PA

Quantum Genomics SA (ALQGC PA) stock market data APIs

€0.44 0.32(256%) as of May 6, 2024

Quantum Genomics SA Financial Data Overview

0.225
0.44
-
-0.2904
-0.12
0.0804-0.195
4 220 K
34 764 K
19 796
0.714
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ALQGC',
Type: 'Common Stock',
Name: 'Quantum Genomics SA',
Exchange: 'PA',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'France',
CountryISO: 'FR',
OpenFigi: NULL,
ISIN: 'FR0011648971',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Quantum Genomics SA Fundamental Data is available in our Financial Data APIs

  • Net Revenue 19 796
  • EBITDA -2 873 480
  • Earnings Per Share -0.83
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Quantum Genomics SA Earnings via APIs

  • Latest Release 2024-04-24
  • EPS/Forecast NaN

Get Quantum Genomics SA End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Quantum Genomics SA latest news via APIs

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments

Firibastat efficacy non-significant versus placebo The REFRESH study and the development of firibastat in cardiology have been stoppedCash of 11 million euros allotted to the development of new innova...
  • CLINICAL STUDY
  • PARIS STOCK EXCHANGE:ALQGC
  • QUANTUM GENOMICS

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments

Quantum Genomics Firibastat efficacy non-significant versus placebo The REFRESH study and the development of firibastat in cardiology have been stopped Cash of 11 million euros allotted to the devel...
  • COMPANY SPECIALISING
  • HEART FAILURE
  • QUANTUM GENOMICS CHIEF FINANCIAL OFFICER
  • RESISTANT HYPERTENSION
Do you have any questions?
support@eodhistoricaldata.com